Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
K Chamoto, T Yaguchi, M Tajima, T Honjo - Nature Reviews …, 2023 - nature.com
PD1 was originally discovered in 1992 as a molecule associated with activation-induced cell
death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding …
death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding …
[HTML][HTML] CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy
CA Chambers, MS Kuhns, JG Egen… - Annual review of …, 2001 - annualreviews.org
The T cell compartment of adaptive immunity provides vertebrates with the potential to
survey for and respond specifically to an incredible diversity of antigens. The T cell …
survey for and respond specifically to an incredible diversity of antigens. The T cell …
Ipilimumab for patients with relapse after allogeneic transplantation
MS Davids, HT Kim, P Bachireddy… - … England Journal of …, 2016 - Mass Medical Soc
Background Loss of donor-mediated immune antitumor activity after allogeneic
hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We …
hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We …
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production
JA Brown, DM Dorfman, FR Ma, EL Sullivan… - The Journal of …, 2003 - journals.aai.org
Abstract Programmed death-1 ligand (PD-L) 1 and PD-L2 are ligands for programmed death-
1 (PD-1), a member of the CD28/CTLA4 family expressed on activated lymphoid cells. PD-1 …
1 (PD-1), a member of the CD28/CTLA4 family expressed on activated lymphoid cells. PD-1 …
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen, MS Kuhns, JP Allison - Nature immunology, 2002 - nature.com
The discovery of multiple costimulatory cell surface molecules that influence the course of T
cell activation has increased our appreciation of the complexity of the T cell response. It …
cell activation has increased our appreciation of the complexity of the T cell response. It …
[HTML][HTML] Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength
JG Egen, JP Allison - Immunity, 2002 - cell.com
CD28 and CTLA-4 engagement with B7 expressed by APCs generates critical regulatory
signals for T cell activation. CD28 is expressed on the T cell surface and enhances T cell …
signals for T cell activation. CD28 is expressed on the T cell surface and enhances T cell …
[HTML][HTML] B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse
T Pentcheva-Hoang, JG Egen, K Wojnoonski… - Immunity, 2004 - cell.com
The reported affinity differences between CD28 and CTLA-4 binding to B7-1 and B7-2 may
serve to selectively regulate CD28 and CTLA-4 function by differentially recruiting and/or …
serve to selectively regulate CD28 and CTLA-4 function by differentially recruiting and/or …
New therapies for hepatocellular carcinoma
MA Avila, C Berasain, B Sangro, J Prieto - Oncogene, 2006 - nature.com
Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, is often
diagnosed at an advanced stage when most potentially curative therapies such as resection …
diagnosed at an advanced stage when most potentially curative therapies such as resection …
Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity
DJ Marciani - Drug discovery today, 2003 - Elsevier
Inactivated vaccines require adjuvants to stimulate an immune response. The choice of
adjuvant or immune enhancer determines whether the immune response is effective …
adjuvant or immune enhancer determines whether the immune response is effective …
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
Targeting immune checkpoint receptors has emerged as an effective strategy to induce
immune-mediated cancer regression in the subset of patients who have significant pre …
immune-mediated cancer regression in the subset of patients who have significant pre …